1. Home
  2. GDRX vs ENGN Comparison

GDRX vs ENGN Comparison

Compare GDRX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoodRx Holdings Inc.

GDRX

GoodRx Holdings Inc.

HOLD

Current Price

$2.31

Market Cap

702.3M

Sector

Technology

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$8.01

Market Cap

647.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDRX
ENGN
Founded
2011
1999
Country
United States
Canada
Employees
N/A
82
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
702.3M
647.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GDRX
ENGN
Price
$2.31
$8.01
Analyst Decision
Buy
Buy
Analyst Count
9
6
Target Price
$3.66
$21.08
AVG Volume (30 Days)
1.3M
245.0K
Earning Date
05-06-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
125.00
N/A
EPS
0.09
N/A
Revenue
$796,853,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.38
N/A
P/E Ratio
$25.56
N/A
Revenue Growth
0.57
N/A
52 Week Low
$1.77
$2.66
52 Week High
$5.61
$12.25

Technical Indicators

Market Signals
Indicator
GDRX
ENGN
Relative Strength Index (RSI) 55.57 53.86
Support Level $2.11 $7.83
Resistance Level $2.47 $8.14
Average True Range (ATR) 0.10 0.55
MACD 0.02 0.15
Stochastic Oscillator 68.92 54.89

Price Performance

Historical Comparison
GDRX
ENGN

About GDRX GoodRx Holdings Inc.

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: